Breast Cancer Chemosensitivity
|
Edited By:Dihua YuThe University of Texas M.D. Anderson Cancer Center Mien-Chie Hung The University of Texas M.D. Anderson Cancer Center ISBN: 978-0-387-74037-9 Published: 2007-08-30 This book may be purchased as an eBook (pdf) for $99, or individual chapters (pdf) may be purchased from the list below for $19. |
Breast cancer is the most common cancer and the second leading cause of cancer death in American women. Despite advances in early detection and the improved understanding of the molecular basis of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease and need effective systemic treatment. Cytotoxic chemotherapies, hormonal therapies, and immunotherapeutic agents are used in the adjuvant, neoadjuvant, and metastatic setting. Systemic agents are generally active at the beginning of therapy in the majority of breast cancers. However, progression occurs after a variable period of time when resistance to therapy develops. In this book, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients.
Chapters available from this book
Therapy-Induced Apoptosis in Primary Tumors
David J. McConkey
An enormous body of literature has accumulated over the past 15 years implicating apoptosis (programmed cell death) in breast cancer cell death induced by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key compone...
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer
Ana Maria Gonzalez-Angulo, Flavia Morales-Vasquez and Gabriel Hortobagyi
Breast cancer is the most common cancer and the second leading cause of cancer death in American women. It was the second most common cancer in the world in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer bio...
Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story
Yong Liao, Dihua Yu and Mien-Chie Hung
The adenoviral E1A-mediated sensitization to a variety of anti-cancer drug-induced apoptosis is a well-established phenomenon on different types of cell systems. However, the mechanisms underlying E1A-mediated chemosensitization are still not fully understood. Recent studies demonstrate that E1A-med...
EGF Receptor in Breast Cancer Chemoresistance
Robert B. Dickson and Tushar Baran Deb
Acquisition of resistance of breast cancer to chemotherapy is commonly associated with progression of the disease to increased metastatic spread. Although early studies on this problem examined the possible roles of chemotherapy drug metabolism and efflux by resistant breast cancer cells, more recen...
Insulin-Like Growth Factors and Breast Cancer Therapy
Xianke Zeng and Douglas Yee
Despite improvements in breast cancer therapy in recent years, additional therapies need to be developed. New therapies may have activity by themselves or may have utility in combination with other agents. Population, preclinical, and basic data suggest the insulin-like growth factor (IGF) system fu...
Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance
M. Tien Kuo
ATP binding cassette (ABC)-containing drug efflux transporters play important roles in regulating intracellular drug concentrations that determine cell sensitivity to chemo-therapeutic agents. Of particular relevance to cancer chemotherapy are the transporters P-glycoprotein (Pgp) encoded by multidr...
Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?
Laura Lambert and Khandan Keyomarsi
Deregulation of the G1 cyclin, cyclin E, has been shown to be both the most powerful predictor of prognosis in early stage breast cancer as well as a significant determinant of tumor aggressiveness. It may also contribute to treatment failure due to chemoresistance. Because some form of cell cycle d...
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance
Ming Tan and Dihua Yu
The erbB2 (also known as HER2 or neu) gene encodes a 185-kDa transmembrane glyco-protein, which belongs to the epidermal growth factor receptor (EGFR) family. ErbB2 is a receptor tyrosine kinase with intrinsic tyrosine kinase activity. The mammalian EGFR family comprises four receptors (EGFR, ErbB2,...
Integrin-Mediated Adhesion: Tipping the Balance between Chemosensitivity
Mary M. Zutter
The integrin family of extracellular matrix receptors plays an important role in normal development, epithelial morphogenesis, angiogenesis, and in tumor progression and metastasis. Integrins cooperate with growth factor receptors to control many cellular functions including proliferation and cell s...
Estrogen Receptors in Resistance to Hormone Therapy
Matthew H. Herynk and Suzanne A.W. Fuqua
Estrogen and its receptors a and b (ERa and ERb) play a major role in tumor progression and approximately two-thirds of breast cancers express these functional receptors. Thus, the ER is a major target for current and developing therapies. Although most ER-positive tumors initially respond to hormon...
p53, BRCA1 and Breast Cancer Chemoresistance
Kimberly A. Scata and Wafik S. El-Deiry
The tumor suppressor genes p53 and BRCA1 are involved in hereditary as well as sporadic breast cancer development and therapeutic responses. While p53 mutations contribute to resistance to chemo- and radiotherapy, BRCA1 dysfunction leads to enhanced sensitivity to DNA damaging therapeutic agents. Th...
